Table 2.
IL-1 blockade in the treatment of inflammatory diseasesa
| Classic autoinflammatory diseases |
| Familial Mediterranean fever [95–97] |
| CAPSb [57, 71, 72, 98] |
| Hyper-IgD syndrome, mevalonic aciduria [99–101] |
| Adult and juvenile Still's disease [56, 102–105] |
| Behçet's disease [106] |
| Schnitzler's syndrome [107–109] |
| TNF receptor-associated periodic syndrome [110–112] |
| PAPA syndrome; Blau's syndrome; Sweet's syndrome [113] |
| Probable autoinflammatory diseases |
| Macrophage activation syndrome [114, 115] |
| Urticarial vasculitis [116] |
| Antisynthetase syndrome [117] |
| Relapsing chondritis [118] |
| Common diseases mediated by IL-1β |
| Urate crystal arthritis (gout) [119–123] |
| Type 2 diabetes [53, 69, 70] |
| Smoldering multiple myeloma [11] |
| Postmyocardial infarction heart failure [124] |
| Osteoarthritis [125] |
aEach responsive to reduction in IL-1β activity
bCAPS is a grouping of familial cold autoinflammatory syndrome, Muckle-Wells syndrome, and neonatal onset multi-inflammatory disease
PAPA pyogenic arthritis, pyoderma gangrenosum, and acne